<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">Harm reduction for PWID has an important role to play in the hepatitis C elimination agenda. In sensitivity analyses, we tested the impact that scaling up prevention measures among PWID could have on the testing requirements, vaccination requirements, and costs of achieving the incidence reduction target. Consistent with previous modelling [
 <xref ref-type="bibr" rid="CR7">7</xref>, 
 <xref ref-type="bibr" rid="CR28">28</xref>], increasing prevention programmes was found to increase the impact of testing and treatment by reducing the need for retreatment (Additional file 
 <xref rid="MOESM1" ref-type="media">1</xref>: Appendix D). Therefore, programmes such as needle and syringe distribution and opioid substitution therapy should be considered essential components of viral hepatitis strategies as recommended by the WHO [
 <xref ref-type="bibr" rid="CR29">29</xref>].
</p>
